Geode Capital Management LLC Purchases 1,855,907 Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Geode Capital Management LLC grew its position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) by 1,600.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,971,894 shares of the company's stock after purchasing an additional 1,855,907 shares during the quarter. Geode Capital Management LLC owned approximately 105.45% of Tonix Pharmaceuticals worth $650,000 as of its most recent filing with the Securities and Exchange Commission (SEC).Get Tonix Pharmaceuticals alerts:Pharma Frenzy: Volatility Ignites Biotech SectorSeparately, Commonwealth Equity Services LLC bought a new position in shares of Tonix Pharmaceuticals during the fourth quarter worth $40,000. 82.26% of the stock is currently owned by institutional investors. Analysts Set New Price TargetsTNXP has been the topic of a number of research reports. Noble Financial reiterated an "outperform" rating and issued a $70.00 price target on shares of Tonix Pharmaceuticals in a report on Thursday, March 20th. StockNews.com started coverage on Tonix Pharmaceuticals in a research report on Monday, February 10th. They issued a "sell" rating on the stock.Is Tonix Pharmaceuticals the Next Biotech Breakout? View Our Latest Analysis on Tonix PharmaceuticalsTonix Pharmaceuticals Trading Up 10.9 %Shares of TNXP opened at $20.00 on Monday. Tonix Pharmaceuticals Holding Corp. has a fifty-two week low of $6.76 and a fifty-two week high of $672.00. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The company's fifty day moving average is $16.88 and its 200 day moving average is $20.69. The stock has a market capitalization of $128.70 million, a PE ratio of 0.00 and a beta of 1.50. Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last announced its earnings results on Tuesday, March 18th. The company reported ($9.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.23) by ($3.54). The business had revenue of $2.58 million for the quarter, compared to analysts' expectations of $3.20 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. Sell-side analysts expect that Tonix Pharmaceuticals Holding Corp. will post -1762.5 earnings per share for the current fiscal year. Tonix Pharmaceuticals Company Profile (Free Report)Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.Further ReadingFive stocks we like better than Tonix PharmaceuticalsWhy Invest in 5G? How to Invest in 5G Stocks Western Digital: Is the Storage Sector Set for a Rebound?A Deeper Look at Bid-Ask SpreadsWingstop Stock Jumps on Q1 Beat, Expansion Outlook3 Stocks to Protect Your Portfolio from the Coronavirus Contagion Why Energy Stocks Like Exxon and Hess Are Back in FocusThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Tonix Pharmaceuticals Right Now?Before you consider Tonix Pharmaceuticals, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tonix Pharmaceuticals wasn't on the list.While Tonix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here